✦ LIBER ✦

Evaluation of Cisplatin and Cyclosporin A in Recurrent Platinum-Resistant Ovarian Cancer: A Phase II Study of the Gynecologic Oncology Group

✍ Scribed by Alberto Manetta; John A. Blessing; Jean A. Hurteau

Book ID: 112247268
Publisher: Elsevier Science
Year: 1998
Tongue: English
Weight: 29 KB
Volume: 68
Category: Article
ISSN: 0090-8258
DOI: 10.1006/gyno.1997.4887

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II Trial of Pyrazoloacridine in Re

Phase II Trial of Pyrazoloacridine in Recurrent Platinum-Sensitive Ovarian Cancer: A Gynecologic Oncology Group Study

✍ Steven C. Plaxe; John A. Blessing; Michael A. Bookman; William T. Creasman 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 39 KB

A phase II evaluation of tirapazamine pl

A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study

✍ Allan Covens; John Blessing; David Bender; Robert Mannel; Mark Morgan 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 101 KB

Altretamine (Hexamethylmelamine) in Plat

Altretamine (Hexamethylmelamine) in Platinum-Resistant and Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Phase II Trial

✍ Maurie Markman; John A. Blessing; David Moore; Harrison Ball; Samuel S. Lentz 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Phase II evaluation of three-day topotec

Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma : A Gynecologic Oncology Group study

✍ David Scott Miller; John A. Blessing; Samuel S. Lentz; D. Scott McMeekin 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 1 views

## Abstract ## BACKGROUND Topotecan, administeredintravenously at a dose of 1.5 mg/m^2^ per day for 5 days every 21 days, is an established regimen in the treatment of recurrent ovarian carcinoma. Alternate dosing strategies have sought to improve toxicity. The authors evaluated the tolerability a

A phase II evaluation of bortezomib in t

A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study

✍ Carol Aghajanian; John A. Blessing; Kathleen M. Darcy; Gary Reid; Koen DeGeest; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 589 KB

Phase II Evaluation of 24-h Continuous I

Phase II Evaluation of 24-h Continuous Infusion Topotecan in Recurrent, Potentially Platinum-Sensitive Ovarian Cancer: A Gynecologic Oncology Group Study

✍ Maurie Markman; John A. Blessing; Ronald D. Alvarez; Parviz Hanjani; Steven Wagg 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 42 KB